MRNA — All updates

20 entries loaded; 0 direction changes

Filter loaded records
Schwab NetworkPublished 2026-11-05
“The Big 3: HCA, ISRG, MRNA”
$MRNANo side taken
AI summary · The speaker likes MRNA, citing Phase 3 data showing a Keytruda-partnered drug cuts skin-cancer-related deaths by about 42% and an upward trend since the start of this year, though not a long-term upward trend. But it failed near old highs around 255 and RSI is unresolved between rising and falling trendlines; a breakout beyond either is needed to clarify bullish vs bearish direction, and a break below the 238.25 5-day EMA could open 219.

Your last name here is also in the healthcare sector, but it's a pharmaceutical company that has fallen a little more than some of the others, down 4.3% for Moderna, which has been making headlines a lot so far this year.

Well, the big picture for Moderna: everyone knows them from their COVID vaccine, but they also have some cool things they're working on, like the partnership with Keytruda and the drug they've provided that's reached Phase 3, which currently shows it can reduce skin cancer-related deaths by about 42%.

So, this is good news. So, I like Moderna in a long-term trend, I shouldn't say a long-term upward trend. It has been on an upward trend since the beginning of this year.

Meet KevinPublished 2026-11-04
“The Stock Market & Morning After Election 2026.”
$MRNABullish
Meet KevinPublished 2026-10-31
“You've been WARNED.”
$MRNABullish
BenzingaPublished 2026-10-30
“$INTC Plunges 26%, $AMZN Drops 6% After Q3 Earnings | PreMarket Playbook | October 30, 2026”
$MRNABearish
AI summary · MRNA is not a stock to hold: it has never made any money and is a 'flim flam' company, though intraday trading in and out is fine. It has looked strong — a 545% run, then a William Blair downgrade to market perform — and 180 was a good buy-the-dip entry.

MRNA, only down a couple.

Wow. MRNA. Yeah. Where is mRNA? mRNA is not going down. William Blair takes a shot at Madna stock downgrade to market outperform after 545% run. That was October 27th, so that's not Yeah, that that looks strong for sure.

Uh, what do you think of MNA MRNA? It's just looking good. You know, that was such a buy the dip at 180. I got involved at 180. I didn't hold it long enough though when it went down from 240 on the leaked news. That was that was a good opportunity.

The Motley FoolPublished 2026-10-23
“Moderna CEO Reveals His Massive Plans for Cancer, AI & Beyond!!”
$MRNABullish
AI summary · The host expects to keep adding to his Moderna position, arguing the market misprices its platform: at a typical 10% industry approval rate the stock would be overvalued, but the platform should lift success rates in each new disease area, with autoimmune value not yet in the share price.

Since we only have 3 hours, I'll start asking questions right away. Okay, let's start by explaining Moderna's basic technology in a way that a tenth-grade student who hates science can understand.

Oh, come on, man. You can't hate science in high school. Well, very simply, as many of you have learned during the pandemic, messenger RNA (mRNA) is an information molecule. It consists of four letters, just as all software consists of zeros and ones.

Schwab NetworkPublished 2026-10-23
“Friday's First Moves: MRNA Cancer Vaccine Trial Leaks, DECK Earnings, NCLH Downgrade”Cited source: analysts
$MRNANo side taken
Schwab NetworkPublished 2026-10-23
“WDC & BE Slide After Earnings as Crude Crosses $100; MRNA Cancer Vaccine Data Leak”
$MRNANo side taken
AI summary · Moderna's leaked phase 3 cancer-vaccine data showed a 42% reduction in recurrence/death risk vs 40% expected; some hoped for above 50%, and survival data had not leaked. The stock fell partly after a sharp prior rise; the speaker calls the leaked results overall positive, pending final results due end of week.

Okay, let's move on to talking about a big stock in the Nasdaq index. Not so much today, but yesterday. This is the company "Moderna". It's a completely different story from technology stock trading here.

There was a lot of optimism ahead of what would happen this weekend. We are supposed to get the results of the cancer vaccine trials. We have obtained the first stage and the second stage.

There was a leak yesterday that caused the stock to drop. Tell us about some of the price movements that are happening here.

Meet KevinPublished 2026-10-20
“The NEXT Frontier: THESE 3 Stocks Boom”
$MRNABullish
AI summary · MRNA is a long-term bullish holding: AI cuts cancer-target selection from 60 days to two weeks, enabling faster, cheaper cancer treatment. The October 24 Saturday Phase 3 presentation is the nearest catalyst and could disappoint; MRNA depends on this single treatment, and a bad report could send it back to the bottom.

Moderna has a meeting coming up this Saturday. It will be a presentation, and they deliberately do this when the market is closed. It will be a presentation on October 24th. This is the closest catalyst, an update to their Phase 3 cancer treatment data,

So, what does Moderna do? Moderna basically says: " Hey, let's examine someone's cancer. We'll take a solid cell from the cancer, and we'll surgically remove part of it. We'll take a biopsy."

So, we're going to take a biopsy of, you know, a cancer cell. And then, what we're going to do is genome sequencing...oh my god. We will be doing a genome sequence for that, which, as you know, is a very long series of genetic data.

Think of the letters T, A, and C. Remember your biology days, right? What we will try to do is try to find in that cancer cell parts of its genome that we can target to destroy it, which of course means that we do not want to target parts of that genome that, if targeted, could kill you.

Obviously, this is a problem. We want to target parts of that genome that are unique to that cancer cell . The problem is that cancer cells mutate all the time. It's constantly changing.

Therefore, this basic genome changes a lot. Therefore, what we will do is target 32 different parts. If any one of these parts survives, we will still be able to target that cancer cell.

What we will do is we will inject these small parts into your body, perhaps seven times over a 12-month course. We will train your body. We won't go into the exact science behind it, because it gets a bit complicated with protein folding and predicting what ultimately happens inside your lymph nodes.

Simply put, there are small carriers, okay? These small carriers will be trained on these thirty-two parts . These thirty-two small parts will be taken and attached to its outer surface.

You will take it to your lymphatic system and say to it, "Do you see all these little bumps we have here? Eliminate them. Eliminate these little proteins we are carrying. Identify them and eliminate them."

And then your lymphatic system will say: "We don't like this. We're going to ...we're going to ...we're going to... make a face. There we go . A face. We're going to go after those little bumps."

Well, these bumps are really hard to identify, and that's where artificial intelligence comes in. Because they can travel throughout your entire body, locate them, track down that cancerous cell and eliminate it to prevent it from spreading to the rest of your body, right?

The whole idea is that even if that cancer cell is mutating or evolving, as long as we have one of those remaining parts , we can still identify it. That's the idea. The problem is that this selection process used to take about 60 days, and you would only get two of them.

Maybe only two parts. Good? That has changed thanks to artificial intelligence. Now artificial intelligence comes along and says, "We can do a lot of this in about two weeks." We can get 32 expected chips that we actually believe will: first, eliminate cancer, and second, will not end your life.

Both things are somewhat important, aren't they? Therefore, artificial intelligence speeds up the time it takes to do this,

Brian ShannonPublished 2026-10-20
“Brian Shannon on TraderTV Live 10/20/26”
$MRNANo side taken
Meet KevinPublished 2026-10-20
“The Pain Returns... ALREADY AI, Fed, Iran, SpaceX”Cited source: Bank of America
$MRNABullish
AI summary · MRNA is a bullish but binary bet: he is exposed, bought around 135 to 145, and is excited about the Oct 24 phase 3 cancer-therapy update, AI-driven cost/time gains and possible expansion to other cancers; BofA's target is 220, but it carries single-trial risk, and a bad Saturday report could send it back to the floor.

I mean, the Q's are holding. Look at that bounce. Was that a VWAP bounce? Uh-huh. Yeah. Perfect VWAP.

Some of the stocks we'll touch on here are going to be Tempest AI, Mona, and Eli Liy. Now, I want to be clear out of these three, I've got exposure to two of them.

So the first thing to know is that Merna has a meeting coming up this Saturday. Uh it is going to be a presentation. They purposefully do it when the market is closed. Is going to be a presentation on October 24th.

It's the nearest catalyst and it is an update on phase 3 data for their cancer therapy which is the partnership between uh mona and merks keduda cancer therapy or amunotherapy drug uh in fighting stage 4 melanoma and minimizing the risk of spread throughout your body metastasis.

Verified InvestingPublished 2026-10-16
“Tesla Unveils a Flying Car, Then Stock CRASHES”
$MRNABearish
AI summary · Moderna jumped roughly 200% on its skin cancer drug advancing to the next trial phase and, after consolidating, has stepped higher, but it just printed its biggest red candle since that jump and the RSI is diverging bearishly against higher price highs; a decline would not surprise him and he would not fight that move.

We'll take a look at SpaceX and Moderna,

Then we have a "cancer cure" candle, right? Or that leap in the candle there . Okay, this is Moderna. You see that they got that good treatment for skin cancer, you know, move on to the next trial.

The skin cancer drug, of course, moved on to the next phase of trials. The stock jumped based on that news.

Brian ShannonPublished 2026-10-06
“Brian Shannon on TraderTV 10/6/26”
$MRNABearish
AI summary · MRNA faces likely short-term decline/shake-out; key support at 20-day MA (~173-174), next level ~152 if broken.

There you go. So, we have seen the bottom of Nike, as you said, as you said . There is another appeal, and it is from a few weeks ago. So I forgive you if you don't remember this, but do you remember Moderna 130?

Yes. So, that was that support level, the breakout at Moderna. At this point, we now have a triple top here. You broke out above the peak, you hit a triple top. These are of course not all-time highs; it was higher during COVID, but you have a triple top.

We saw a significant capitulation in this sector today. Everything was opened higher and was subsequently fully punished. It wasn't a huge volume today, but it was a clear rejection.

So, what do you expect for Moderna now? Is there a next entry level, because it is clearly still in an upward trend and everyone is wondering what the next step is, since it has performed so well.

Schwab NetworkPublished 2026-09-30
“Wednesday's First Moves: MRNA Downgrade, BA Jet Contract, JBL Earnings”Cited source: Citigroup
$MRNABearish
AI summary · MRNA is a sell; Citi downgraded to Sell with $80 target (>60% downside) as the 200% rally on cancer trials is fully priced in and valuation assumes excessive future oncology success.

We view Moderna as a "sell" product. Citigroup gave it a "sell" rating today. This comes after Moderna's recent strong performance, thanks to some positive trial results . They have downgraded its rating to "Sell" from " Neutral".

At the same time, they raised the target price for the stock, but only to 80. This is a rise from 60. So, their outlook wasn't very positive before today. This means a potential drop of more than 60% from yesterday's closing levels.

Brian ShannonPublished 2026-09-29
“Brian Shannon on TraderTV Live 9/29/26”
$MRNANo side taken
AI summary · MRNA momentum is unpredictable; a break above 190 could lead to a pullback toward 175 before further upside.

there is a question from one of our viewers. He asked what you think of mRNA and how this bull flag originated. Do you think there will be a continuation, or do you think the momentum will slowly fade?

I look at it and say that no one can predict where the momentum will fade. So instead, I look at it and say: look at the 30-minute timeframe, and it is innocent until proven guilty.

It moves along with this rising 5-day moving average. So I would say that you should look at the most recent relevant higher low above that 5-day moving average. So I think that if we break through the 190, the most likely scenario for mRNA is that it does something like this: maybe we start to divide, break through that lower bottom here, see a lower top, get stuck below the 5-day average, and then maybe pull back a bit towards the 175, and then it is ready to rise again.

BenzingaPublished 2026-09-23
“$AMD Joins $1T Club, NASDAQ ATH? | PreMarket Playbook | September 23, 2026”
$MRNABullish
AI summary · MRNA has strong momentum from a resolved bull pennant; likely upside to 200+, but faces resistance near 210-215 and is technically extended.

AMJ Wellness Matters is mentioning Madna. We talked about that a little bit earlier. Let's see how that's resolved here. 190s. This kept trading. Oh man, Madna all green candles both buying or excuse me both price and volume.

Yeah, this is um this a really nice resolution of a bull penant uh formation that we had that started uh back in August when we got that news of I forget exactly what the news was, but is I think that regarding using AI personalized mRNA vaccines for things like cancer and stuff.

StockCharts TVPublished 2026-09-22
“The BEST Chart in All 11 Sectors (September 2026)”
$MRNABullish
AI summary · MRNA technical structure shows accumulation after gap and consolidation.

The first arrow, literally in the 99.9 percentile, is Moderna, its code is MRNA. Clearly, this name has become familiar to many of us during the COVID-19 pandemic. Moderna and Pfizer were key names to watch.

But look how this stock rebounded in 2026, and how its rise has accelerated remarkably in the recent period. Six weeks. A large price gap to the upside occurred in mid-August following the approval of a drug, and prices have since consolidated.

BenzingaPublished 2026-09-21
“Oil Tanks, Futures Rally but 10-Year Nears 5% | PreMarket Playbook | September 21, 2026”
$MRNABullish
AI summary · MRNA bullish pattern resolution targets 180+, with potential for profit-taking due to overbought conditions.

MRNA is going to be next here. Bigab is mentioning that this is rolling here today. Like we had what an 11 point move here on Madna. 14 10% move here. Look at Madna ripping out of the gate here.

Wait a minute. I got to look at this cuz we talked about how this was breaking out of consolidation. It was bull flagging and or bull penant and here we are. We are moving up. Uh looks like what is it 175?

So the high was 1766. Uh I mean to me this looks like we're getting a resolution of this bullish pattern here. And uh that means we'll probably end up seeing 180 maybe more.

BenzingaPublished 2026-09-17
“Stocks Shrug Off A Hawkish Fed? | PreMarket Playbook + All Access | September 17, 2026”
$MRNABullish
AI summary · MRNA is in a technical breakout; 130 is support, 175 is the key resistance/breakout target.

Uh Madna up 10 plus percent here today. And look at this. This also breaking out of this structure. Now, I know we talk a lot about islands here. There's definitely price history to the left.

So, that's one thing. We never actually came back into the bottom of this candle, but boy oh boy, this 130 looked like some pretty good support. Now it actually looks like your next target here might be 176. That's Madna MRNA.

What they said to watch for
Brian ShannonPublished 2026-09-11
“Stock Market, Bitcoin, Gold Analysis for Week Ending 9/11/26”
$MRNANo side taken
AI summary · MRNA remains choppy; buyers not yet in control, but potential for renewed leadership if range tightens.

we know uh the genomics stocks kind of lit this group on fire a couple weeks ago with the mRNA move and mRNA has really just been you know very choppy. If we put an anchor on the event it provides zero value basically the fiveday moving average is rising in here.

So, I think that, you know, you look at it and say we found buyers along the 20-day moving average. Maybe an inside day on Monday, tighten the range, and then uh MRNA might be able to uh establish some leadership once again, but it's still a little bit too early uh to say that the buyers are gaining control in there.

Brian ShannonPublished 2026-09-08
“Brian Shannon Trader TV Live 9/8/26”
$MRNANo side taken
AI summary · MRNA is poised for a significant move (powder keg) that should resolve soon.

Good point about mRNA being the driver, because that stock feels like a powder keg about to explode. That's it. Hopefully, it happens soon and settles the matter. I mean, I think Moderna has something going for it, Moderna really set that in motion, and you were 100% right about that.

See older →
All updates for other tickers
Follow $MRNA30-day free trial
Start trial